8月19日，佰仁医疗今日收盘121.43元，下跌1.54%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到98.10倍，总市值167.27亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入1.00亿元，同比31.30%；净利润3250.43万元， 同比290.69%，销售毛利率85.72%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13佰仁医疗98.10114.3113.00167.27亿行业平均 59.4955.005.10121.17亿行业中值40.1939.642.9559.18亿1九安医疗11.6511.780.92196.54亿2英科医疗 15.3616.561.37242.73亿3新华医疗16.2915.101.33104.41亿4山东药玻16.3516.401.88154.62亿5奥美医疗 17.0016.661.7561.43亿6振德医疗17.7516.731.1364.43亿7九强生物17.8516.602.1988.42亿8康德莱 18.4018.421.5339.66亿9奥泰生物18.5619.571.5059.18亿10维力医疗18.5719.84 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Baijun Medical, which has a current stock price of 122.3 yuan, a PE ratio of 98.80, and a total market capitalization of 16.847 billion yuan [1][2] - Baijun Medical's revenue for Q1 2025 reached 100 million yuan, representing a year-on-year increase of 31.30%, while net profit surged to 32.5043 million yuan, up 290.69% year-on-year, with a gross profit margin of 85.72% [1] - The company ranks 104th in the medical device industry based on PE ratio, which has an average of 56.58 and a median of 39.97 [1][2] Group 2 - As of March 31, 2025, Baijun Medical had 3,099 shareholders, an increase of 288 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of Baijun Medical includes the research, production, sales, and service of medical devices, with key products such as biological patches for cardiac and thoracic surgery, artificial heart valves, and other surgical implant devices [1]

8月14日，佰仁医疗今日收盘119.24元，下跌2.09%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到96.33倍，总市值164.25亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.76倍，行业中值39.14倍，佰仁医疗排 名第104位。 最新一期业绩显示，2025年一季报，公司实现营业收入1.00亿元，同比31.30%；净利润3250.43万元， 同比290.69%，销售毛利率85.72%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13佰仁医疗96.33112.2512.76164.25亿行业平均 55.7651.784.91117.92亿行业中值39.1439.592.8556.79亿1九安医疗11.1811.310.88188.72亿2英科医疗 14.7815.931.32233.49亿3山东药玻16.1716.211.86152.90亿4新华医疗16.3115.111.33104.53亿5振德医疗 17.0416.061.0861.87亿6奥美医疗17.0716.731.7561.68亿7九强生物17.6516.412.1687.42亿8康德莱 18 ...

北京佰仁医疗科技股份有限公司的主营业务是医疗器械的研发、生产、销售及服务。公司的主要产品是 心外科生物补片、胸外科生物补片、神经外科生物补片、人工生物心脏瓣膜、经导管主动脉瓣系统、瓣 膜成形环、肺动脉带瓣管道、涤纶补片及其他外科植入医疗器械产品等。 最新一期业绩显示，2025年一季报，公司实现营业收入1.00亿元，同比31.30%；净利润3250.43万元， 同比290.69%，销售毛利率85.72%。 8月4日，佰仁医疗今日收盘115.99元，上涨6.11%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到93.70倍，创69天以来新低，总市值159.77亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均54.32倍，行业中值38.11倍，佰仁医疗排 名第104位。 截至2025年一季报，共有12家机构持仓佰仁医疗，其中基金12家，合计持股数219.70万股，持股市值 2.26亿元。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13佰仁医疗93.70109.1912.41159.77亿行业平均 54.3250.504.72116.17亿行业中值38.1137.682.705 ...

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Baijun Medical, which closed at 109.31 yuan with a 3.73% increase, resulting in a rolling PE ratio of 88.30 times and a total market value of 15.057 billion yuan [1] - The average PE ratio for the medical device industry is 53.65 times, with a median of 37.22 times, positioning Baijun Medical at the 104th rank within the industry [1][2] - As of the first quarter of 2025, 12 institutions hold shares in Baijun Medical, with a total of 2.26 million yuan in market value [1] Group 2 - Baijun Medical specializes in the research, production, sales, and service of medical devices, with key products including various types of biological patches and heart valve systems [1] - The latest financial results for the first quarter of 2025 show Baijun Medical achieved an operating income of 100 million yuan, a year-on-year increase of 31.30%, and a net profit of 32.5043 million yuan, reflecting a significant year-on-year growth of 290.69% [1] - The sales gross margin for Baijun Medical stands at 85.72% [1]

Group 1 - The core viewpoint of the article highlights that Baijun Medical's stock closed at 101.9 yuan, down 1.26%, with a rolling PE ratio of 82.11 times and a total market value of 14 billion yuan [1] - The average PE ratio for the medical device industry is 51.29 times, with a median of 37.02 times, placing Baijun Medical at the 103rd position in the industry ranking [1] - As of March 31, 2025, Baijun Medical has 3,099 shareholders, an increase of 288 from the previous count, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Group 2 - Baijun Medical's main business includes the research, production, sales, and service of medical devices, with key products such as biological patches for cardiac and thoracic surgery, artificial heart valves, and other surgical implant products [1] - In the latest quarterly report for Q1 2025, the company achieved a revenue of 100 million yuan, a year-on-year increase of 31.30%, and a net profit of 32.5 million yuan, reflecting a significant year-on-year growth of 290.69%, with a gross profit margin of 85.72% [1]